Clinical Trials Logo

Left Ventricular Thrombus clinical trials

View clinical trials related to Left Ventricular Thrombus.

Filter by:

NCT ID: NCT03786757 Not yet recruiting - Clinical trials for ST Segment Elevation Myocardial Infarction

Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)

Start date: April 1, 2019
Phase: Phase 3
Study type: Interventional

Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events. This study aims to assess the efficacy and safety outcomes of Rivaroxaban on the prevention of post-STEMI left ventricular thrombus.

NCT ID: NCT03764241 Recruiting - Clinical trials for ST Segment Elevation Myocardial Infarction

Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant

EARLYmyo-LVT
Start date: February 1, 2020
Phase: Phase 3
Study type: Interventional

Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events. This study aims to assess the efficacy and safety outcomes of Rivaroxaban on the treatment of post-STEMI left ventricular thrombus.

NCT ID: NCT03415386 Not yet recruiting - Clinical trials for Acute Myocardial Infarction

Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus

OATH-AMI
Start date: June 2020
Phase: Phase 4
Study type: Interventional

A multi-center study will be done to explore the optimal regimen of antithrombotic therapy for acute myocardial infarction with left ventricular mural thrombus. The investigators will evaluate the different combinations of antiplatelet drugs and anticoagulants for at least one month, such as aspirin 100mg qd+clopidogrel 75mg qd+warfarin (INR1.8-2.2), aspirin 100mg qd+clopidogrel 75mg qd+dabigatran 110mg bid, aspirin 100mg qd+ticagrelor 60mg bid+warfarin (INR1.8-2.2), and aspirin 100mg qd+ticagrelor 60mg bid+dabigatran 110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel 75mg qd/ticagrelor 60mg bid. Then the investigators will complete the 12-month follow-up to evaluate the efficacy and safety of the optimal antithrombotic therapy regimen for acute myocardial infarction with left ventricular mural thrombus.